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Background: Prevalence and distribution of pathogenetic mutations in BRAF and NRAS genes were evaluated in
multiple melanoma lesions from patients with different geographical origin within the same Italian population.
Methods: Genomic DNA from a total of 749 tumor samples (451 primary tumors and 298 metastases) in 513
consecutively-collected patients with advanced melanoma (AJCC stages III and IV) was screened for mutations in
exon 15 of BRAF gene and, at lower extension (354/513; 69%), in the entire coding DNA of NRAS gene by
automated direct sequencing. Among tissues, 236 paired samples of primary melanomas and synchronous or
asynchronous metastases were included into the screening.
Results: Overall, mutations were detected in 49% primary melanomas and 51% metastases, for BRAF gene, and 15%
primary tumors and 16% secondaries, for NRAS gene. A heterogeneous distribution of mutations in both genes was
observed among the 451 primary melanomas according to patients’ geographical origin: 61% vs. 42% (p = 0.0372)
BRAF-mutated patients and 2% vs. 21% (p < 0.0001) NRAS-mutated cases were observed in Sardinian and non-
Sardinian populations, respectively. Consistency in BRAF/NRAS mutations among paired samples was high for lymph
node (91%) and visceral metastases (92.5%), but significantly lower for brain (79%; p = 0.0227) and skin (71%;
p = 0.0009) metastases.
Conclusions: Our findings about the two main alterations occurring in the different tumor tissues from patients
with advanced melanoma may be helpful in improving the management of such a disease.
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Melanoma is characterized by a high tendency to
metastasize and a striking resistance to conventional ther-
apies other than surgery [1,2]. Recently, kinase-targeted
therapies and immunostimulatory antibodies or a combin-
ation of them have been successfully introduced into the
treatment of melanoma [3-7]. From the pathogenetic point
of view, melanoma is a complex disease that arises thor-
ough activation of several crucial cell-signaling pathways* Correspondence: gpalmieri@yahoo.com
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distribution, and reproduction in any medium[8,9]. A better comprehension of the molecular mecha-
nisms underlying the development and progression of
melanoma is valuable in assessing the different bio-
logical subset of patients to be addressed to the most
appropriate therapy.
Among others, the mitogen-activated protein kinase
(MAPK) signal transduction pathway, which includes
the cascade of NRAS, BRAF, MEK1/2, and ERK1/2 gene
products, plays a major role in the pathogenesis of mel-
anoma [10-12]. A high frequency of somatic mutations
in NRAS and BRAF genes has been reported in both
nevi and cutaneous melanomas, suggesting that such al-
teration may represent early events in the development
of melanocytic tumors [13-15]. Furthermore, melanomastral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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usually carry either a mutated NRAS or mutated BRAF
(somatic mutations in such genes have been reported as
mutually exclusive) [14,16,17].
Recently, our group demonstrated the occurrence of
quite similar rates of BRAF-NRAS mutations among dif-
ferent types of metastasis, with a high consistency between
primary melanomas and lymph node or visceral metasta-
ses, in contrast with a significantly lower consistency be-
tween primary tumors and brain or skin metastases [18].
The aim of this study was to evaluate prevalence and dis-
tribution of pathogenetic mutations in BRAF and NRAS
genes among melanoma patients with different geograph-
ical origin within the same Italian population. In particu-
lar, we compared the BRAF/NRAS mutation frequencies
between patients originating from Sardinia, whose popula-
tion is considered genetically homogeneous due to its high
rate of inbreeding and the subsequent inheritance of many
common genetic traits [19,20], and those originating from
other parts of Italy, whose genetic background is markedly
heterogeneous (like that in vast majority of the general
populations from Western countries). Finally, we extended
the investigation about the distribution of BRAF-NRAS
mutations to a larger series of different melanoma tissues.
Patients and methods
Patients
Five hundred and thirty-two patients with histologically-
proven diagnosis of advanced melanoma (disease stages III
and IV, according to American Joint Committee on Cancer
guidelines [21]) were included into the study. Among them,
19 cases were excluded due to tissue DNA degradation; the
remaining 513 cases had primary (N = 313) or metastatic
(N = 62) or both (N = 138) tumor tissue samples available
for mutation analysis. Patients were enrolled consecutively
between June 2008 and March 2013 from centers in Italy.
To avoid bias, patients were included regardless of age of
onset, cancer family history, and disease characteristics.
Sardinian or non-Sardinian (including cases from the cen-
tral and southern regions in Italy) origin was ascertained in
all cases through genealogical studies (place of birth of all
patients and their parents was carefully assessed in order
to assign their geographical origin). About one-fifth of the
present cohort (108 patients) had been tested for BRAF
and NRAS somatic mutations previously [18].
Patients were informed about the study aims and
limits, and provided written consent for the molecular
analysis on their tissue samples. The study was reviewed
and approved by the ethical review boards at participat-
ing centers.
Samples
Formalin-fixed, paraffin-embedded (FFPE) tumor tissues
were obtained from pathological archives. To improvesensitivity of nucleotide sequencing, the neoplastic portion
of each tissue section was isolated in order to obtain
tumor samples with at least 80% neoplastic cells. Histo-
logical classification - including Breslow thickness, Clark’s
level, and disease stage at diagnosis - was confirmed by
medical records, pathology reports, and/or review of
pathological material.
Mutation analysis
Genomic DNA was isolated from FFPE tumour tissues,
using the QIAamp DNA FFPE tissue kit (QIAGEN Inc.,
Valencia, CA, USA). The full coding sequences and
splice junctions of NRAS (exons 2 and 3), and the entire
sequence of the BRAF exon 15 (nearly all pathogenetic
mutations of BRAF have been detected at the kinase do-
main at this genomic level [10]) were screened for muta-
tions. All samples included into the study were assessed
for the quality of the purified DNA, in order to avoid
that discrepant cases could arise from technical prob-
lems such as the insufficient sample quality.
Sequencing conditions as well as primer sets and PCR
assay protocols were as previously described [18,22].
Briefly, sequencing analysis was conducted in duplicate -
starting from two different tumor sections and performing
two different PCR-based amplifications - and in both
DNA strands for all samples. For discordant tumors, the
sequence analysis was performed in triplicate - three dif-
ferent tumor sections and three different PCR-based am-
plifications, in order to avoid any chance of PCR artifacts.
A nucleotide sequence was considered as valid when the
quality value (QV) was higher than 20 (<1/100 error prob-
ability), using a reference sequence for each of the ana-
lyzed exons (2 and 3 for NRAS, 15 for BRAF). In this
study, the QV average was 35 (range, 30–45; <1/1000-1/
10,000 error probability).
Statistical analysis
Presence of BRAF or NRAS mutations was statistically
correlated with different variables (sex, age at diagnosis
and anatomical site of the primary melanoma, geograph-
ical origin of the patient) using the Pearson's Chi-Square
test. The exact coefficient for sample proportion analysis
was performed to determine all significant parameters
(below 0.05 level). All analyses were performed using the
statistical package SPSS/7.5 per Windows.
Results
Patients and samples
Genomic DNA from 513 consecutively-collected pa-
tients with advanced melanoma (AJCC stages III and IV
[21]) was screened for somatic mutations in the exon 15
of BRAF gene. For a large fraction of patients whose
DNA was available (354/513; 69%), mutation analysis
was also carried out in the entire coding sequences of
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exons and intron-exon junctions were analyzed by direct
sequencing using an automated approach.
Majority of patients included into the study were
males (277/513; 54%) and presented a disease with
lymph node involvement (AJCC stage III, 319/513; 62%);
median age was 55 years, with a range from 21 to 89
years (Table 1). Considering the anatomical site of the
primary melanomas, trunk was the most frequent loca-
tion (trunk, 243 [47%]; limbs, 205 [40%]; head and
neck, 54 [11%]; unknown, 11 [2%]); median Breslow
thickness was 2.1 mm (range, 0.78-8.3 mm). About
one third (192/513; 37%) of patients originated from
Sardinia; the remaining patients were from other geo-
graphical areas within central and Southern parts of
Italy (Table 1). No substantial difference was observed
in patients’ characteristics between the Sardinian and
the non-Sardinian series.
Primary tumor tissues were the only available samples
in a large fraction of patients (313/513; 61%). Among
the remaining 200 patients, paired samples of primary
melanomas and synchronous or asynchronous metasta-
ses were obtained from about one fourth of cases (138/
513; 27%), whereas metastatic tumor tissues represented
the only available specimens for about one tenth of cases
(62/513; 12%) (Figure 1). Overall, a total of 749 tumor
samples (451 primary melanomas and 298 melanoma
metastases) was screened for BRAF mutations; among
them, available DNA from 528 specimens (312 primary
melanomas and 216 melanoma metastases) was analyzed
for mutations in NRAS gene.Table 1 Characteristics of analyzed patients
Characteristics Number of patients %
Total analyzed 513
Males/Females 277/236 54/46
Median age (years) 55
Range 21-89
AJCC stage
III 319 62
IV 194 38
Primary site
Head and neck 54 11
Limbs 205 40
Trunk 243 47
Unknown 11 2
Geographical origin
Sardinian 192 37
non-Sardinian 321 63
Abbreviation: AJCC American Joint Committee on Cancer.Mutation analysis
Mutations in BRAF gene were detected in 223/451
(49%) primary melanomas and 153/298 (51%) metastatic
tissues, whereas NRAS mutations were found in 46/312
(15%) primary tumors and 34/216 (16%) melanoma me-
tastases (Table 2). In our series, no concomitant muta-
tions of BRAF and NRAS genes were detected. Overall,
BRAF or NRAS mutations were observed in 376/749
(50%) or 80/528 (15%) melanoma tissue samples, re-
spectively (Table 2). Considering the cases analyzed for
mutations in both genes, we identified a BRAF or NRAS
mutation in 339/528 (64%) melanoma lesions.
Among the metastatic tissue samples, with the excep-
tion of the brain metastases [BRAF, 21/46 (46%); NRAS,
10/46 (22%)], a quite identical frequency of BRAF and
NRAS mutations was observed across the different types
of metastasis: lymph nodes [BRAF, 78/151 (52%); NRAS,
15/102 (15%)], visceral lesions [BRAF, 25/47 (53%);
NRAS, 4/30 (13%)], and subcutaneous lesions [BRAF,
29/54 (54%); NRAS, 5/38 (13%)] (Table 2).
According to the patients’ geographical origin, distri-
bution of mutations among the 451 primary melanomas
was significantly heterogeneous for both genes: for
BRAF, 109/178 (61%) vs. 114/273 (42%) mutated patients
were observed in Sardinian and non-Sardinian popula-
tions, respectively (p = 0.0372); for NRAS, 2/105 (2%) vs.
44/207 (21%) mutated cases were observed in Sardinian
and non-Sardinian populations (p < 0.0001) (Table 2).
Nearly all BRAF mutations across samples were of the
BRAFV600E subtype (347/376; 92.3%). All but one of the
remaining BRAF variants were represented by other
V600 subtypes: V600K (20/376; 5.3%), V600D (6; 1.6%),
and V600R (2; 0.5%) (Table 3). The L597R variant (1/
376; 0.3%) was therefore the only mutation not affecting
the codon 600 of BRAF, though it is a sequence variation
still localized into the active kinase domain of the gene
(Table 3). For NRAS, all deleterious mutations were
found at the codon 61 of the gene: Q61R (47/80; 58.8%),
Q61L (23; 28.7%), and Q61K (10; 12.5%) (Table 3). All
mutations detected in this study have been reported
previously in the Human Gene Mutation Database
(HGMD) at http://www.hgmd.cf.ac.uk/ac/index.php and
in the Catalogue Of Somatic Mutations In Cancer (COS-
MIC) at http://www.sanger.ac.uk/genetics/CGP/cosmic/.
Among the 236 paired samples of primary and second-
ary melanomas, 202 (86%) showed concordant mutation
patterns between primary tumors and metastatic lesions.
In particular, rates of consistency in BRAF/NRAS muta-
tions between primary and secondary tumors varied
according to the anatomical sites of metastasis: 109/120
(91%; p = 0.1123), for metastases in lymph nodes; 37/40
(92.5%; p = 0.4316), for visceral metastases; 19/24 (79%;
p = 0.0227), for brain metastatic lesions; 37/52 (71%; p =
0.0009), for skin secondaries (Table 4). Synchronous
Figure 1 Patients and tissues included into the study.
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of the total amount of secondary lesions) showed a
slight, non-significant higher rate of consistency in com-
parison to that found among asynchronous metastases
[40/44 (91%) vs. 162/192 (84%), respectively] (Table 4).
Considering the 34 paired samples with discrepancies
in BRAF/NRAS mutation patterns between primary and
secondary tumors, majority of them (18; 53%) displayed
a wild-type primary tumor and a mutated metastasis (14
in BRAF and 4 in NRAS), a second large fraction of
cases (14/34; 41%) presented with a mutated primary
tumor and a wild-type metastasis (13 in BRAF and 1 in
NRAS), and the remaining limited subgroup of samples
(2/34; 6%) carried a change in mutation pattern be-
tween the two tumor lesions (an NRAS mutation in pri-
mary melanoma and a BRAF mutation in melanoma
metastasis) (Table 5).
With the exception of the age at diagnosis, the fre-
quency of BRAF mutations was not correlated with any
clinicopathological parameters in primary melanomas.
The prevalence of BRAF mutations was significantly
higher in patients with onset age of 50 years or younger
(101/166; 60.8%) as compared with those older than 50
years (122/285; 42.8%) (p = 0.0431). No correlation was
instead observed between NRAS mutations and clinico-
pathological parameters. The BRAF/NRAS mutationstatus was not evaluated for association with clinical out-
come in our series.
Discussion
The NRAS and BRAF genes encode two important pro-
teins belonging to the mitogen-activated protein kinase
(MAPK) signal transduction pathway, which regulates
cell growth, survival, and invasion [12,23,24]. Mutations
in these genes have been widely implicated in several as-
pects of development and progression of melanoma
[25,26]. In the present study, we evaluated the spectrum
and distribution of somatic mutations in NRAS and
BRAF genes in a large series of melanoma tissues (N =
749, including 451 primary melanomas and 298 melan-
oma metastases), excised from patients with different
geographical origin within the Italian population.
Overall, BRAF mutations were observed in half of our
tissue sample collection (376/749; 50.2%), whereas NRAS
mutations were detected in about one seventh of ana-
lyzed cases (80/528; 15.1%). Since BRAF and NRAS mu-
tations were found to be mutually exclusive (further
confirming previous data [23]), a high prevalence of such
alterations was observed in our series, with about two
thirds of melanomas presenting a BRAF/NRAS muta-
tion. All detected BRAF or NRAS variants have been
previously demonstrated to be oncogenic and able to
Table 2 Prevalence of BRAF/NRAS mutations in melanoma
tissues
Type of sample BRAF NRAS
mutated mutated
(%) (%)
Primary tumour 223/451 46/312
(49%) (15%)
Sardinian 109/178 2/105
patients (61%) (2%)
non-Sardinian 114/273 44/207
patients (42%) (21%)
Metastasis 153/298 34/216
(51%) (16%)
Lymph node 78/151 15/102
(52%) (15%)
Visceral 25/47 4/30
(53%) (13%)
Liver 16/30 3/22
(53%) (14%)
Lung 9/17 1/8
(53%) (12%)
Skin 29/54 5/38
(54%) (13%)
Brain 21/46 10/46
(46%) (22%)
Total lesions 376/749 80/528
(50%) (15%)
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motes cell proliferation and survival. With the exception
of the BRAFL597R variant, all mutations occurred in co-
dons V600 and Q61 of BRAF and NRAS genes, respect-
ively (see Table 3). While the rates of the mutation
subtypes in NRAS gene were comparable with those de-
scribed in majority of previous reports, the BRAFV600E
mutation represented the most preponderant BRAF vari-
ant in our series (92.3%), with an incidence of the other
BRAFV600 mutation subtypes much lower (about 7%)
than that reported in Australian population (ranging
from 26% to 30%) [27-29].
Considering the different types of metastatic lesions,
rates of BRAF and NRAS mutations were highly similar
across the lymph node (52%, for BRAF, and 15%, for
NRAS), visceral (53% and 13%), and skin (54% and 13%)
metastases (see Table 2). Although the total amount of
BRAF/NRAS mutated cases was quite identical to that of
the other secondary lesions, brain metastases surpris-
ingly presented a markedly divergent distribution of
BRAF (46%) and NRAS (22%) mutations.A quite similar frequency of either BRAF or NRAS
mutations was observed among primary and metastatic
melanomas: 49% vs. 51%, for BRAF, and 15% vs. 16%,
for NRAS, respectively (see Table 2). On this issue
some controversial data have been provided. The lack
of a significant difference in BRAF/NRAS mutations
between primary and secondary melanomas in our
series seems to be consistent with previous data indicat-
ing that BRAF/NRAS mutations may occur early in
the development of melanoma and, therefore, their
incidence may not vary significantly during tumor pro-
gression [30,31]. Furthermore, the presence of BRAF
mutations in nevi [13-15] suggests that activation of the
RAS/RAF/MEK/ERK pathway may participate to initi-
ation of melanocytic transformation as well as that
BRAF activation is necessary for inducing cell prolifera-
tion but not sufficient for the development of melanoma
(additional molecular events are thus required to achieve
full malignancy). Conversely, the demonstration of a se-
quential increase in mutation rates for both BRAF and
NRAS genes in a subset of melanomas during progres-
sion of the disease - from in-situ to invasive melanomas
[32,33] or from primary to metastatic melanoma lesions
and melanoma cell lines in a more limited series previ-
ously analyzed by our group [18] - also suggests that
BRAF/NRAS mutations can not be strictly considered as
founder events in melanomagenesis for the totality of
cases (in truth, a slightly increased incidence of such
mutations, moving from primary to metastatic lesions,
was indeed registered in this study).
A significantly higher frequency of BRAF mutations
was present in primary melanoma patients from
Sardinia, as compared to those from the other parts of
Italy (61% vs. 42%; p = 0.0372), whereas a significantly
higher prevalence of NRAS mutations was found in cases
from Middle-South Italy, as compared to those from
Sardinia (21% vs. 2%; p < 0.0001). The Sardinian popula-
tion (1.67 million in 2010, according to the Italian Na-
tional Institute of Statistics) is considered genetically
homogeneous, since it is isolated and has experienced lit-
tle immigration due to its remote location [19,20]; con-
versely, the remaining Italian populations are genetically
heterogeneous and similar to the mixed ones into the
Western countries. Our observations strongly suggest that
different “genetic background” may induce discrepant
“penetrance” and distribution of somatic mutations in can-
didate cancer genes. On this regard, one could speculate
that mechanisms of transformation underlying the patho-
genesis of melanoma may differ in distinct populations.
This represents a further confirmation of previous results
on germline DNA from different collections of melanoma
patients, indicating that genetic factors involved in suscep-
tibility to melanoma are geographically heterogeneous and
strictly dependent on patients’ origin [34,35].
Table 3 Mutations in BRAF/NRAS genes
Exon Mutation Base change Amino acid change Mutated samples %
BRAF
15 V600E 1799 Val to Glu 347 92.3
T > A
15 V600K 1798-99 GT > AA Val to Lys 20 5.3
15 V600D 1799-1800 Val to Asp 6 1.6
TG > AT
15 V600R 1798-99 Val to Arg 2 0.5
GT > AG
15 L597R 1790 Leu to Arg 1 0.3
T > G
NRAS
3 Q61R 182 Gln to Arg 47 58.8
A > G
3 Q61L 182 Gln to Leu 23 28.7
A > T
3 Q61K 181 Gln to Lys 10 12.5
C > A
Frequencies are related to the total amount of mutated cases in BRAF (N = 376) and NRAS (N = 80) genes.
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BRAF/NRAS mutated cases was however identical
among the Sardinian (61%, for BRAF, and 2%, for NRAS;
total frequency, 63%) and non-Sardinian (42%, for BRAF,
and 21%, for NRAS; total frequency, 63%) patients in our
series. These findings seem to suggest that the MAPK
pathway may be activated - through occurrence of either
BRAF or NRAS mutations - in a maximal fraction of
about two thirds of melanoma cases. While the different
mutation frequencies in such cancer genes could be
explained by differences into the genetic background re-
lated to distinct patients’ origin, there is no clear explan-
ation about the putative existence of a limit in rates ofTable 4 Consistency between primary and secondary melano
Tissue types Consistency secondary/primary melanomas (%
Lymph node 109/120
metastasis (90.8%)
Visceral metastasis 37/40
(92.5%)
Brain 19/24
metastasis (79.2%)
Skin 37/52
metastasis (71.2%)
TOTAL 202/236
(85.6%)oncogenic activation of the MAPK pathway. Prospect-
ively, evaluation of a larger collection of data from mel-
anoma series screened worldwide for somatic mutations
in both genes may provide additional clues about this
issue. Nevertheless, our findings indicate that the muta-
tion prevalence for any candidate cancer gene needs to
be accurately assessed in each geographical area.
Thirty-four paired samples (14.4%) out of 236 analyzed
demonstrated discrepancies in BRAF/NRAS mutation
patterns between primary and secondary tumors; a sig-
nificant discrepancy was only observed in subcutaneous
(28,8%; p = 0.0009) or cerebral metastases (20.8%; p =
0.0227). Although at a non-significant rate, discrepanciesma lesions, according to the BRAF/NRAS mutation status
) Synchronous metastases Asynchronous metastases
25/26 84/94
(96.2%) (89.4%)
3/3 34/37
(100%) (91.9%)
1/1 18/23
(100%) (78.3%)
11/14 26/38
(78.6%) (68.4%)
40/44 162/192
(90.9%) (84.4%)
Table 5 Mutation patterns in discrepant cases
Tissue types Discrepancy secondary/
primary melanomas (%)
Primary tumour Metastasis
BRAF NRAS BRAF NRAS
Lymph node metastasis 11/120 V600K wt wt wt
wt wt L597R wt
wt wt V600E wt
wt wt V600E wt
wt wt V600E wt
(9.2%) V600E wt wt wt
wt wt V600E wt
V600E wt wt wt
V600E wt wt wt
wt wt V600E wt
V600E not tested wt not tested
Visceral metastasis 3/40 V600E wt wt wt
wt wt V600E wt(7.5%)
wt wt V600E wt
Brain metastasis 5/24 V600E wt wt wt
wt wt V600E wt
wt wt wt Q61L(20.8%)
wt wt wt Q61L
wt wt wt Q61R
Skin 15/52 wt wt wt Q61L
V600E wt wt wt
V600E wt wt wt
wt Q61R wt wt
wt Q61R V600E wt
wt Q61R V600E wtmetastasis (28.8%)
wt wt V600E wt
wt wt V600E wt
V600E wt V600E wt
wt wt V600E wt
wt wt V600E wt
V600E wt wt wt
wt wt V600E wt
V600E not tested wt not tested
V600E not tested wt not tested
Abbreviation: wt wild-type.
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metastases (15.6% vs. 9.1%, respectively). In half of the
discrepant cases, we found a wild-type primary tumor
and a mutated metastasis (78% BRAF and 22% NRAS).
In the remaining discrepant cases, we surprisingly ob-
served a mutated primary tumor and a wild-type metas-
tasis (93% BRAF and 7% NRAS) or, to a less extent, a
different mutation pattern between melanoma lesions(NRAS mutation in primary and BRAF mutation in sec-
ondary tumors) (see Table 5). While for the first half of
the discrepant cases, one could infer that selection of
BRAF/NRAS mutant alleles may occur during tumor
progression, for the second series, one could speculate
that primary melanoma may be heterogeneous with
different tumor cell types (one mainly represented and
the others less represented, which may be able to
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of cases). In this sense, molecular heterogeneity as well
as polyclonality of BRAF mutations in primary melano-
mas have been widely reported [33,36,37].
Although pathogenetic mechanisms underlying melan-
oma development and progression are multiple and still
largely unknown, classification of melanoma patients
through the assessment of the molecular profile in pri-
mary tumors and/or correspondent metastases is be-
coming mandatory. In clinical practice, our future efforts
will be aimed at unveiling which gene or pathway could
be truly affected in which subset of patients, in order
to achieve the best treatment and management of the
disease. With the present study, we provided add-
itional clues about the spectrum and distribution of
the two main alterations frequently occurring in the
different tumor tissues from patients with advanced
cutaneous melanoma.
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